47 results about "Antibody Suppression" patented technology

The present invention provides receptors for the growth differentiation factor (GDF) family of growth factors and methods of identifying such receptors. Also included are methods of identifying antibodies which bind to the receptors, peptide fragments of the receptor which inhibit GDF binding, GDF receptor-binding agents capable of blocking GDF binding to the receptor. The receptors of the invention allow the identification of antagonists or agonists useful for agricultural and human therapeutic purposes.

The present invention provides anti-PCI antibodies having Protein C inhibitor (PCI)-neutralizing activity, and the uses thereof. Through the generation and screening of anti-PCI antibodies, the inventors successfully isolated anti-PCI antibodies which inhibit PCI's inhibitory effect on the production and activity of activated Protein C (aPC). The antibodies of the present invention suppress PCI's inhibitory effect on aPC production and/or the aPC inactivation by PCI, and thus can be used to maintain aPC activity and sustain the effects of aPC physiological activities, such as suppression of the activation of blood coagulation system and anti-inflammatory functions. The present invention also provides uses of the antibodies of the present invention in treating diseases such as thrombosis and sepsis using aPC. In treatments by aPC administration, the therapeutic effect of aPC can be sustained by administering an antibody of the present invention. The antibodies of the present invention can be used in the treatment and prevention of diseases such as thrombosis and sepsis.

The invention discloses an SARS-CoV-2 antibody detection method. The SARS-CoV-2 antibody detection method comprises the following steps: carrying out horseradish peroxidase labeling on recombinant SARS-CoV-2Nucleocapsid protein, meanwhile, selecting an anti-SARS-CoV-2 antibody or a dominant antibody to coat the enzyme-linked plate and sealing; according to a competitive ELISA principle, simultaneously adding a to-be-detected sample and an enzyme-labeled antigen into a test hole of an enzyme-linked plate, performing incubation at room temperature, thoroughly washing the plate, then adding a substrate TMB, performing color development in a dark place, finally, terminating the reaction, measuring a light absorption value at 450 nm, and evaluating the titer of the antibody in the sample by calculating the antibody inhibition rate. According to the method disclosed by the invention, relatively conservative N protein in SARS-CoV-2 and a specific antibody of the N protein are selected as rawmaterials. Compared with a traditional antibody detection method, the detection of the Anti-SARS-CoV-2 specific antibody is completed more quickly, more conveniently and more sensitively, and the method has specificity, sensitivity, accuracy and precision and has important application prospect and value.

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.

Provided herein are lipid-based nanoparticles (e.g., exosomes) having (a) a core comprising a cationic polymer and a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug) and (b) a lipid coating comprising an exosomes-derived membrane. Furthermore, the present invention provides methods of producing such nanoparticles as well as methods for use of such lipid-based nanoparticles in therapy.

The invention discloses an antitumor vaccine, an encoding gene, an expression vector, an expression engineering bacteria and application of targeted VEGF and mucin1, and belongs to the technical field of biology. An antitumor vaccine fusion protein adopts VEGF165, VEGF165b or corresponding modified VEGF mutants as an epitope vector, at least one section of epitope peptide of tumor related antigen mucin1 is connected to an end N or an end C of the vector to form the antitumor vaccine having a double target effect. The VEGF in the vaccine can be used as the epitope vector to improve the antigenicity of the mucin1 epitope connected with the VEGF, the over-expressed mucin1 tumor cells are killed, the VEGF can also be used as an antigen to produce an antibody for VEGF so as to inhibit the generation of tumor vessels and cut off the nutrient supply of the tumor. Meanwhile, the epitope vector has a heparin-binding domain which can be bond with heparin sepharose, thereby facilitating the subsequent protein purification.

The present invention relates to a Gremlin-1 antibody that inhibits Gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on Gremlin-1, and therefore, can be effectively used in treating cancer or immune disease.

Methods of inhibiting inflammation and macrophage infiltration following spinal cord injury and methods of modulating the release of TNF-α from cells expressing α-d are disclosed. Anti-α-d monoclonal antibody was used to block the binding between α-d and VCAM-1. A hybridoma secreting the antibody and a diagnostic method using the antibody are disclosed.

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.

A non-naturally occurring variant of a C-terminal fragment of a Plasmodium merozoite surface protein-1 (MSP-1) wherein said variant has (i) a reduced affinity, compared with a naturally occurring Plasmodium MSP-119, for at least one first antibody capable of blocking the binding of a second antibody, which second antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 and (ii) substantially the same affinity for at least one third antibody compared with said naturally occurring Plasmodium MSP-119. which third antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 is provided for use in an anti-malarial vaccine.

Living cells modified at their surface with specially selected polymers are disclosed. A simple method to covalently attach specially selected PEG derivatives to the surface of RBC in aqueous media under mild conditions is a preferred example. The selected PEG-modification dramatically reduced aggregation and low shear viscosity of RBC resuspended in autologous plasma, and inhibited RBC agglutination by blood group-specific antibodies. The morphology and deformability of the PEG-treated cells were unaltered. The PEG coating of the RBC surface is applicable to the treatment of a variety of diseases characterized by vaso-occlusion or impaired blood flow, e.g., myocardial infarction, shock, and sickle cell disease.

The invention provides a recombinant phage peculiar smellremoval vaccine for boars. In the vaccine, recombinant T7 phage is used as an antigen; gonadotropin-releasing hormone (GnRH) protein shown as SEQ ID No:2 in amino acid sequences is expressed on the surface of the recombinant T7 phage; and the GnRH protein is expressed by inserting three copied GnRH genes into the downstream of a P10B gene of the T7 phage. The recombinant phage peculiar smell removal vaccine has the advantages that: (1) the recombinant phage vaccine prepared from a T7 phage carrier can overcome the defect of poor immunogenicity of a GnRH peptide hormone, improve immunogenicity effectively, stimulate organisms to generate an antibody with a higher level and inhibit the development of testicles of the boars; (2) the T7phage is easy to cultivate and purify, and has multiple advantages when used for producing genetic engineering vaccines, so the recombinant phage peculiar smell removal vaccine is convenient to produce in large scale and low in cost; and (3) an immunological method is more humanistic, so the conventional castration method is replaced, and the requirements of modern large-scale feeding and management are met.

The invention provides a molecular marker for an eimeria tenella sensitive strain and a drug-resistant strain and application of the molecular marker. The molecular marker is ATPase (EtASNA1) homologous with eimeria tenella ASNA1. The invention finds that the transcription and protein expression of mRNA of a diclazuril drug-resistant strain and a maduramycin drug-resistant strain are obviously higher than that of the sensitive strain; and the influence of drug stimulation on the EtASNA1 transcription level is detected through an in-vitro culture experiment and an in-vivo experiment, and the invention finds that addition of drugs can cause up-regulation of expression. An antibody inhibition test detects that the EtASNA1 participates in invasion of host cells by polypides. Research results show that the EtASNA1 may participate in invasion, growth and development of eimeria tenella, may be closely related to formation of drug resistance of the eimeria tenella, and may play an important role in resisting drugs.

The invention relates to an inhibition ELISA (Enzyme-Linked Immunosorbent Assay) method for detecting a foot-and-mouth disease virus antibody and application, and belongs to the technical field of biotechnology. The inhibition ELISA method comprises the following steps of: directly diluting negative and positive serum and detected serum on an ELISA plate coated with a captured antibody, and then adding an equal amount of virus antigen diluted to a working concentration, at the same time, setting at least four-hole virus antigen control (serum diluent with the same volume is added in advance), inhibiting virus antigens from being combined with captured antibodies on an ELISA plate by foot-and-mouth disease type specific antibodies in the detected serum and negative and positive serum, referring to a liquid phase blocking ELISA method for judgment, taking 50% of the average value of OD values of virus antigen control holes as a critical value of 50% inhibition of the virus antigens, thus successfully establishing the inhibition ELISA method for detecting the foot-and-mouth disease antibody.

Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of usein the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

The present invention relates to antibodies or antigen binding fragments thereof that specifically bind to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to a method for the production thereof, pharmaceutical compositions containing said antibodies and uses thereof.